Subscribe To

Price Alert Latest News Economic Calendar News

NBRV / Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call Transcript

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Dan Dolan - CFO Ted Schroeder - CEO Conference Call Participants Carl Byrnes - Northland Capital Markets Thomas Yip - HCW Operator Good morning, and welcome to the Nabriva Therapeutics Second Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note that this event is being recorded today. Read More

Demo Live Account See Partner Details

Content Topics

Nabriva

Therapeutics

NBRV

Schroeder

2022

Results

Earnings

nbrv

Transcript

Stock

Posted: Aug 3 2022, 23:23

Author Name: Seeking Alpha

NBRV News

By Market Watch
November 28, 2022

Nabriva's stock is up after sharing antibiotic news

Shares of Nabriva Therapeutics Plc NBRV, were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data fr

By GlobeNewsWire
November 7, 2022

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engag

By GlobeNewsWire
September 6, 2022

Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company enga

By Seeking Alpha
August 3, 2022

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call Transcript

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Dan Dolan - CFO Ted Schroeder -

By GlobeNewsWire
May 13, 2022

Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference

DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercializatio

By Seeking Alpha
May 8, 2022

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call Transcript

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Dan Dolan - Chief Financial Offic

By Seeking Alpha
March 29, 2022

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q4 2021 Results - Earnings Call Transcript

By GlobeNewsWire
March 15, 2022

Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company enga

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.